An economic evaluation of pneumococcal conjugate vaccines, PCV20 versus PCV15, for the prevention of pneumococcal disease in the Swedish pediatric population by Ann-Charlotte Fridh, Andreas Palmborg, An Ta, Donata Freigofaite, Sophie Warren, Johnna Perdrizet

Get full text

Delayed Transition to 20-Valent Pneumococcal Conjugate Vaccine in Pediatric National Immunization Programs: Forgone Public Health and Economic Benefit by Johnna Perdrizet, An Ta, Liping Huang, Warisa Wannaadisai, Aleksandar Ilic, Kyla Hayford, Ayman Sabra

Get full text

Economic Evaluation of Transitioning to the 20-Valent Pneumococcal Conjugate Vaccine in the Dutch Paediatric National Immunisation Programme by Esra Çakar, An Ta, Michel Peters, Elizabeth Vinand, Angela Waterval-Overbeek, Aleksandar Ilic, Johnna Perdrizet

Get full text

Real-World Impact of Pneumococcal Conjugate Vaccines on Vaccine Serotypes and Potential Cross-Reacting Non-Vaccine Serotypes by Kevin Apodaca, Lindsay R. Grant, Johnna Perdrizet, Derek Daigle, Gabriel Mircus, Bradford D. Gessner

Get full text

Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine (PCV20) to prevent pneumococcal disease in the Greek pediatric population by Charalampos Tzanetakos, Ioanna Kokkinaki, Myrto Barmpouni, Vasiliki Kossyvaki, Marina Psarra, Johnna Perdrizet, George Gourzoulidis

Get full text